Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

The landscape of myeloid and astrocyte phenotypes in acute multiple sclerosis lesions.

Park C, Ponath G, Levine-Ritterman M, Bull E, Swanson EC, De Jager PL, Segal BM, Pitt D.

Acta Neuropathol Commun. 2019 Aug 12;7(1):130. doi: 10.1186/s40478-019-0779-2.

2.

Multiple sclerosis relapse risk in the postoperative period: Effects of invasive surgery and anesthesia.

De Lott LB, Zerafa S, Shedden K, Dunietz GL, Earley M, Segal BM, Braley TJ.

Mult Scler. 2019 Jun 25:1352458519860304. doi: 10.1177/1352458519860304. [Epub ahead of print]

PMID:
31237825
3.

Clinical trials in multiple sclerosis: potential future trial designs.

Manouchehri N, Zhang Y, Salter A, Hussain RZ, Hartung HP, Hemmer B, Linker R, Segal BM, Cutter G, Stüve O.

Ther Adv Neurol Disord. 2019 May 13;12:1756286419847095. doi: 10.1177/1756286419847095. eCollection 2019. Review.

4.

MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis.

Kuhbandner K, Hammer A, Haase S, Terbrack E, Hoffmann A, Schippers A, Wagner N, Hussain RZ, Miller-Little WA, Koh AY, Stoolman JS, Segal BM, Linker RA, Stüve O.

Front Immunol. 2019 Apr 26;10:903. doi: 10.3389/fimmu.2019.00903. eCollection 2019.

5.

Treatment of neuromyelitis optica spectrum disorders.

Romeo AR, Segal BM.

Curr Opin Rheumatol. 2019 May;31(3):250-255. doi: 10.1097/BOR.0000000000000603.

PMID:
30920972
6.

The Diversity of Encephalitogenic CD4+ T Cells in Multiple Sclerosis and Its Animal Models.

Segal BM.

J Clin Med. 2019 Jan 19;8(1). pii: E120. doi: 10.3390/jcm8010120. Review.

7.

Enhancing natural killer cells is beneficial in multiple sclerosis - Commentary.

Segal BM.

Mult Scler. 2019 Apr;25(4):513-514. doi: 10.1177/1352458518809296. Epub 2018 Nov 13. No abstract available.

PMID:
30421650
8.

CNS-resident classical DCs play a critical role in CNS autoimmune disease.

Giles DA, Duncker PC, Wilkinson NM, Washnock-Schmid JM, Segal BM.

J Clin Invest. 2018 Dec 3;128(12):5322-5334. doi: 10.1172/JCI123708. Epub 2018 Oct 29.

9.

An IFNγ/CXCL2 regulatory pathway determines lesion localization during EAE.

Stoolman JS, Duncker PC, Huber AK, Giles DA, Washnock-Schmid JM, Soulika AM, Segal BM.

J Neuroinflammation. 2018 Jul 16;15(1):208. doi: 10.1186/s12974-018-1237-y.

10.

A randomized, subject and rater-blinded, placebo-controlled trial of dimethyl fumarate for obstructive sleep apnea.

Braley TJ, Huber AK, Segal BM, Kaplish N, Saban R, Washnock-Schmid JM, Chervin RD.

Sleep. 2018 Aug 1;41(8). doi: 10.1093/sleep/zsy109.

PMID:
29800466
11.

Modulation of the Innate Immune System: A Future Approach to the Treatment of Neurological Disease.

Segal BM.

Clin Immunol. 2018 Apr;189:1-3. doi: 10.1016/j.clim.2018.03.003. No abstract available.

PMID:
29628125
12.
13.
14.

Myeloid cell plasticity in the evolution of central nervous system autoimmunity.

Giles DA, Washnock-Schmid JM, Duncker PC, Dahlawi S, Ponath G, Pitt D, Segal BM.

Ann Neurol. 2018 Jan;83(1):131-141. doi: 10.1002/ana.25128. Epub 2018 Jan 14.

15.

CD4+ T Cells Orchestrate Lethal Immune Pathology despite Fungal Clearance during Cryptococcus neoformans Meningoencephalitis.

Neal LM, Xing E, Xu J, Kolbe JL, Osterholzer JJ, Segal BM, Williamson PR, Olszewski MA.

MBio. 2017 Nov 21;8(6). pii: e01415-17. doi: 10.1128/mBio.01415-17.

16.

Speaking out about gender imbalance in invited speakers improves diversity.

Klein RS, Voskuhl R, Segal BM, Dittel BN, Lane TE, Bethea JR, Carson MJ, Colton C, Rosi S, Anderson A, Piccio L, Goverman JM, Benveniste EN, Brown MA, Tiwari-Woodruff SK, Harris TH, Cross AH.

Nat Immunol. 2017 Apr 18;18(5):475-478. doi: 10.1038/ni.3707. No abstract available.

17.

Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project.

Dickerson E, Davenport MS, Syed F, Stuve O, Cohen JA, Rinker JR, Goldman MD, Segal BM, Foerster BR; Michigan Radiology Quality Collaborative.

J Am Coll Radiol. 2017 Mar;14(3):371-379.e1. doi: 10.1016/j.jacr.2016.09.037. Epub 2016 Dec 5.

PMID:
27932248
18.

IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation.

Cravens PD, Hussain RZ, Miller-Little WA, Ben LH, Segal BM, Herndon E, Stüve O.

PLoS One. 2016 Oct 25;11(10):e0165248. doi: 10.1371/journal.pone.0165248. eCollection 2016.

19.

An emerging role for eotaxins in neurodegenerative disease.

Huber AK, Giles DA, Segal BM, Irani DN.

Clin Immunol. 2018 Apr;189:29-33. doi: 10.1016/j.clim.2016.09.010. Epub 2016 Sep 21. Review.

PMID:
27664933
20.

Antibodies to the RNA-binding protein hnRNP A1 contribute to neurodegeneration in a model of central nervous system autoimmune inflammatory disease.

Douglas JN, Gardner LA, Salapa HE, Lalor SJ, Lee S, Segal BM, Sawchenko PE, Levin MC.

J Neuroinflammation. 2016 Jul 8;13(1):178. doi: 10.1186/s12974-016-0647-y.

Supplemental Content

Loading ...
Support Center